OTCMKTS:CLXPF Cybin (CLXPF) Stock Price, News & Analysis $6.92 +0.32 (+4.85%) As of 08/21/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Cybin Stock (OTCMKTS:CLXPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cybin alerts:Sign Up Key Stats Today's Range$6.62▼$6.9750-Day Range$6.59▼$9.0052-Week Range$0.49▼$3.38Volume511,182 shsAverage Volume551,962 shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada. Read More Receive CLXPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address CLXPF Stock News HeadlinesCybin gears up for Phase 3 trial in depression treatmentOctober 3, 2024 | uk.investing.comCYBN Stock Earnings: Cybin Beats EPS for Q1 2024August 9, 2024 | investorplace.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year. | Weiss Ratings (Ad)CYBN Stock Earnings: Cybin Beats EPS for Q4 2023June 27, 2024 | investorplace.comCybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programsSeptember 14, 2023 | finance.yahoo.comPsychedelics Companies Join The Race To Develop Much-Needed Anxiety TreatmentJanuary 16, 2023 | benzinga.comCybin Provides Update on its Intellectual Property Portfolio - Business WireOctober 6, 2022 | businesswire.comCybin, GH Research Among Top Psychedelic Movers Of Today - Numinus Wellness (OTC:NUMIF), Compass Pathways - BenzingaOctober 4, 2022 | benzinga.comSee More Headlines CLXPF Stock Analysis - Frequently Asked Questions How have CLXPF shares performed this year? Cybin's stock was trading at $8.82 at the beginning of the year. Since then, CLXPF shares have decreased by 21.5% and is now trading at $6.92. How do I buy shares of Cybin? Shares of CLXPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Holding & Other Investment Offices Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CLXPF CIKN/A Webwww.cybin.com Phone416 567 4675FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.57 Quick Ratio13.57 Sales & Book Value Annual Sales$680 thousand Price / Sales1,512.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book15.73Miscellaneous Outstanding Shares148,598,000Free FloatN/AMarket Cap$1.03 billion OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:CLXPF) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access